anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a drug decreasing or overcoming addiction, and if possible, alleviating or removing the symptoms related to the withdrawal of habit-forming and addictive drugs.  <P>SOLUTION: A composition for use in managing withdrawal from an addictive substance is described. The composition includes one or more peptides having specific activity on εisozyme and/or γisozyme of protein kinase C (PKC). The peptide can be administered prior to, concurrent with or subsequent to administration of the addictive substance. Also there is described a kit having at least one container containing a peptide having isozyme-specific activity on εPKC or γPKC and instructions for use.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase).
Data support preoperative radiotherapy as one of the standard options in the management of large or high-grade extremity soft tissue sarcomas (STS). The advantages of preoperative radiotherapy are lower doses and smaller radiation volumes; these may be used to effect improvement of long-term side effects and extremity function. Another potential advantage is assisting surgery through tumor shrinkage and reduction of tumor cell seeding. The disadvantage of preoperative radiation is the higher likelihood of postoperative wound complications, but in a prospective phase III trial these complications were found to be generally temporary and without significant effect on long term function.

Combined conservative surgery and radiotherapy has shown to achieve excellent local control in sarcoma patients following margin-negative surgery, but late radiation morbidity and reduced quality of life may result from adjuvant radiation. The dosimetric advantage of proton radiotherapy may translate into reduced acute and late effects due to improved normal-tissue sparing in the treatment of extremity and truncal STS. However, these potential advantages need to be validated in clinical trials. The investigators propose a phase II study to evaluate the effect of preoperative proton radiotherapy on the reduction of late radiation morbidity, patterns of failure, and impact of late radiation morbidity on general quality of life (QOL).
PURPOSE: A cosmetic composition containing Paris verticillata extract is provided to suppress MMP-1 generation and to ensure anti-oxidation and cell regeneration. CONSTITUTION: A cosmetic composition for anti-aging or antioxidation contains Paris verticillata extract as an active ingredient. A cosmetic composition for skin regeneration contains the extract as an active ingredient. A cosmetic composition for improving anti-wrinkling or skin elasticity contains the extract as an active ingredient. The extract is contained in 0.00001-30.0%(w/w) based on total weight of the cosmetic composition. The extract is isolated using water, anhydrous or hydrous low alcohol of 1-4 carbon atoms, propylene glycol, butylenes glycol, glycerine, acetone, ethyl acetate, butyl acetate, chloroform, or mixture thereof. The cosmetic composition is manufactured in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing foundation, oil, powder foundation, wax foundation, spray, or mixture thereof.
The present invention relates to health care capsules prepared from aloe extract, which belongs to the field of health care products, particularly to the field of pure natural health care products. The gelatin between aloe leaves is removed to obtain peel which is dried in the sun and ground into a powder. The capsules are composed of 480 to 520 grams of aloe peel dry powder, 140 to 160 grams of angelica, 180 to 220 grams of flowery knotweed, 140 to 160 grams of houttuynia, 90 to 110 grams of plantain herb and 8 to 12 grams of aweto. The dry powder of the aloe leaf peel has the function of protecting other functional medicinal powders which smoothly passes through the stomach and directly reaches the intestinal tract or the sick part, namely that the dry powder mainly serves as a protective agent and a conveying agent. The capsules have obvious effect so as to be favorable for the absorption of other Chinese herbal medicinal components by a human body. Acute toxicity tests and long-term toxicity tests on products indicate that the aloe health care capsules for expelling toxin and nourish the face in the present invention have no toxic or side effect, and have high safety and reliability, and the capsules can be tried by different people so as to obtain fine health care effect.
Drug-eluting stents (DES) substantially reduce restenosis compared with bare metal stents and represent a significant advance in percutaneous coronary interventions (PCIs). Accordingly, DES have been rapidly adopted into practice and are currently used in the majority of PCI procedures. Despite their rapid acceptance, DES are not without limitations. In particular, patients who receive DES (like those who receive conventional bare metal stents) remain at risk of a 1% to 2% incidence of stent thrombosis, which is often associated with devastating consequences like death or myocardial infarction. Understanding and eliminating mediators of stent thrombosis are thus important goals for optimizing the clinical benefits of DES. Delayed endothelial coverage after DES implantation has been demonstrated and is thought to prolong the window of vulnerability to stent thrombosis. Consequently, current recommendations for DES are: dual antiplatelet therapy for at least 12 months in patients at low risk of bleeding, especially with " off-label " use. Because of rare but severe very late stent thrombosis, the dual antiplatelet therapy is more and more prescribed in clinical practice for several years.But it has been clearly demonstrated that the combination of aspirin and clopidogrel (the thienopyridine the most used) significantly increase the rate of severe and moderate bleedings when compared to aspirin alone. This is important if we consider the possibility or the necessity to prolong the combined antiplatelet therapy after stent implantation.ProposalTo compare treatment with aspirin alone versus the combined antiplatelet treatment with aspirin and clopidogrel after 12 months of combined antiplatelet treatment after DES implantation

NB : On the decision of the sponsor, the latest patient monitoring was advanced to September 30, 2014 instead of January 2015.
The group undergoing the intervention will participate in 90-minute group visits occurring weekly for 4 weeks, then biweekly for a total of 26 weeks/15 visits. Each visit will focus on intensive lifestyle changes. Further, these patients will each have the opportunity to meet one-on-one with a member of the research team at the end of each visit in order to discuss individual goals and progress. Pharmacotherapy therapy changes will be recommended to reduce or avoid use of medication which may contribute to weight gain and medications for weight loss will be prescribed as an individualized treatment strategy during one-on-one time with the pharmacist or physician if the patient can afford it and no contraindications exists.
ATRA 10 mg, 2 times a day, orally; The initial dose of eltrombopag was 50 mg/time, once a day. According to the clinical standard of eltrombopag dose adjustment in the research protocol set by the research group, the dose was increased when the platelet count was lower than 5×109/L. The maximum dose is 75 mg/d, the dose is reduced if it is higher than 200×109/L, and the drug is temporarily discontinued when it is higher than 400×109/L, and the drug is repeated according to the platelet count. The treatment course is 12 weeks.
The invention discloses application of retinal pigment epithelial cells and mesenchymal stem cells in preparation of a medicament for treating retinal degenerative diseases. Application of retinal pigment epithelial cells and mesenchymal stem cells of fetal origin in preparing a medicament for treating retinal degenerative diseases. The retinal degenerative disease is preferably age-related macular degeneration. The invention transplants the retina pigment epithelium cell and the mesenchymal stem cell from the fetus to treat the model mouse of the retinal degenerative disease, and has better effect on the repair function after the damage of the retina compared with the simple transplantation of fRPE and MSC. Moreover, compared with the transplantation of only one cell, the co-transplantation has the advantages that the number of the survived cells after the transplantation is more, and the photoreceptor cell rescue effect is stronger. Moreover, the co-transplantation significantly inhibits the inflammatory reaction of a degenerative disease model mouse and promotes the secretion of endogenous growth factors.
Of the 389 patients who received FORTAMET® in controlled Phase III clinical studies, 26.5% [103/389] were 65 years and older. No overall differences in effectiveness or safety were observed between these patients and younger patients.

Controlled clinical studies of immediate-release metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and younger patients. Metformin is known to be substantially excreted by the kidney and because of the risk of serious adverse reactions to the drug is greater in patients with impaired renal function, immediate-release metformin should only be used in patients with normal renal function (see CONTRAINDICATIONS, WARNINGS, and CLINICAL PHARMACOLOGY: Pharmacokinetics). Because aging is associated with reduced renal function, immediate-release metformin should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function. Generally, elderly patients should not be titrated to the maximum dose of immediate-release metformin (see also WARNINGS and DOSAGE AND ADMINISTRATION).
Group 1- The intervention group I will receive a customized strip slipper with a 3mm EVA horseshoe piece (Shore A 32). And 2.5mm EVA cover (Shore A 28).
The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
Participants on previous treatment with growth hormone will have one study visit for taking a non-invasive biological sample. Good responders are defined as participants with a change in height Standard Deviation Score (SDS) more than (\>) 1.0, corresponding to \>85th percentile.
A motion platform combines oscillating single-axis or bi-axial motion and patient biological and behavioral feedback mechanisms for reducing HIIDAA in people experiencing neurological imparities. The platform is driven by actuators that provide single-axis or bi-axial motion. The platform has a planar upper surface on which a wheelchair, chair or other resting furniture can be positioned. The platform motion is actuated based on facial expression and bodily movement recognition feedback, heart rate feedback, standing and fall detection, and/or manual remote control from a wireless or internet enabled device. Noise feedback may also be provided as an input. The device actuation may include oscillating motion to simulate rocking. Music may also be output to further help manage the reduction of HIIDAA of the individual. Reinforcement and deep learning algorithms also use optimal time-dependent actuation profiles based on real-time inputs and a database of behavior characteristics of the patient.
<P>PROBLEM TO BE SOLVED: To provide a Bacillus natto culture extract-containing preparation which prevents the discoloration (black coloration) of the preparation, the characteristic smell of fermented soybeans, and the deterioration of active ingredients such as natto kinase in the Bacillus natto culture extract, and to provide a method for effectively preserving the Bacillus natto culture extract.  <P>SOLUTION: This Bacillus natto culture extract-containing preparation comprises the Bacillus natto culture extract and either of a reducing sugar and a reducing sugar derivative. The reducing sugar derivative is preferably a reducing sugar derivative not having a reducing terminal. Since having a discoloration-inhibiting effect, the Bacillus natto culture extract-containing preparation is especially effective for a transparent capsule preparation. In addition, the deterioration of the Bacillus natto culture extract can be prevented by mixing the Bacillus natto culture extract with the and either of the reducing sugar and the reducing sugar derivative and then preserving the mixture.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The points were selected with reference to the 2006 National Standard of the People's Republic of China (GB/T 12346-2006), "Acupoint Names and Localization". The patients were placed in the prone position, the acupoints were sterilized with 75% alcohol, and the needles were inserted vertically with the conventional needling method, to the extent that there was a sensation of acidity, numbness, heaviness, distension, or radiating to the surroundings, and the needles were left in place for 15 min. The treatments were carried out twice a week for a total of five treatments.
The recommended dose of Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets is one tablet twice daily administered on an empty stomach with water for adults and children 12 years of age and older. It is recommended that the administration of Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets with food should be avoided. A dose of one tablet once daily is recommended as the starting dose in patients with decreased renal function. (See CLINICAL PHARMACOLOGY and PRECAUTIONS.)

Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets must be swallowed whole and never crushed or chewed. Occasionally, the inactive ingredients of Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets may be eliminated in the feces in a form that may resemble the original tablet. (See PRECAUTIONS, Information for Patients.)
We conducted a large surveillance study among members of an integrated healthcare delivery system in Pacific Northwest of the United States to estimate medical costs attributable to medically attended acute gastroenteritis (MAAGE) on the day care was sought and during 30-day follow-up. We used multivariable regression to compare costs of MAAGE and non-MAAGE cases matched on age, gender, and index time. Differences accounted for confounders, including race, ethnicity, and history of chronic underlying conditions. Analyses included 73,140 MAAGE episodes from adults and 18,617 from children who were Kaiser Permanente Northwest members during 2014-2016. Total costs were higher for MAAGE cases relative to non-MAAGE comparators as were costs on the day care was sought and costs during follow-up. Costs of MAAGE are substantial relative to the cost of usual-care medical services, and much of the burden accrues during short-term follow-up.
Hepatitis C virus (HCV) infection is one of the major public health problems worldwide . Chronic HCV infection is characterized by a high rate of progression to fibrosis, chronic hepatitis, leading to cirrhosis and ultimately to hepatocellular carcinoma (HCC). Early detection is critically important because the most effective treatment for HCC is surgical resection or ablation therapy when the tumour is small. On the other hand, genetic factors can also contribute, particularly gene polymorphisms of inflammatory cytokines and growth factor ligands and receptors . Vitamin D is involved in the metabolism of skeleton as a systemic hormone but also has important roles in the regulation of host immune responses, fibrogenesis and development of cancer through vitamin D receptor (VDR). Previous data have suggested that vitamin D levels may influence cancer development. In particular, several single nucleotide polymorphisms have been described in the VDR gene, and some polymorphisms are associated with tumor occurrence. For instance, VDR polymorphisms have been related to cancers of the breast, prostate, skin, colon-rectum, bladder and kidney, although with conflicting observations. VDR polymorphisms have also been investigated in the context of some chronic liver diseases, such as chronic hepatitis B, primary biliary cirrhosis and autoimmune hepatitis . In a recent published study, VDR polymorphism may be used as a molecular marker to predict the risk and to evaluate the disease severity of HCC in patients with chronic hepatitis B.

A significant association of VDR ApaI polymorphism with the development of HCC in chronic HCV infection may help to identify those who are at high risk of developing HCC.
Purabond is a new medical device taking the form of a gel containing an active ingredient called RADA-16. It is designed to stop bleeding from wounds by forming into a stable barrier (matrix) when coming into contact with ionic fluids like blood. Purabond is already currently use for procedures by Cardiology, General Surgery, Vascular, Gynaecology, and ENT. Specific uses in ENT surgery so far have been for sinus surgery. Purabond is CE marked and indicated for situations where haemostasis by standard means is insufficient or impractical.

The investigators hypothesise that Purabond will reduce the duration for which neck drains must be left in place after neck dissection, which is an operation to remove lymph nodes from the neck. Following neck dissection, fluid can leak into the healing tissues in the neck from very small damaged blood vessels - when an excess of this fluid builds up underneath the skin this is called a seroma. This occurs in 1.3-7% of patients and represents a potential area for infection as well as a noticeable lump. Readmission is sometimes required in the event of an infected seroma though there is no published evidence on how common this is. Drains are placed during neck dissection surgery to remove this fluid and to also reduce the overall seroma rate. Drains are left in until the volume of fluid being produced decreases. The duration for which drains are left in place is also affected by the development of other, rarer complications - specifically chyle leak, anastomotic leak, and pharyngocutaneous fistula. In the setting of any of the above, drains are often left in for longer to ensure any fluid that accumulates is removed and that dead space in the neck is kept to a minimum.

This study aims to assess if Purabond can speed up the process of removing drains. The fluid that makes up a seroma leaks out from damaged blood vessels in the same way a haematoma (collection of blood in the neck) does but the vessels of interest in a seroma are smaller and more numerous - manual ligation of these is not feasible. As Purabond forms a matrix in response to ionic fluids (including seroma) it is expected to reduce the rate of seroma by sealing such vessels. The benefits of this would be reduced duration of stay in hospital for patients with otherwise uncomplicated neck dissections but also reducing infection risk to patients with more complex needs who could otherwise have their drains removed earlier. It would also be expected to reduce the subsequent need for readmission and aspiration of seroma. These findings would then be more broadly applicable to less extensive neck surgeries where there is a risk of seroma but drains are not placed frequently (parotidectomy, thyroidectomy, etc).
Impairment in visual function is common after traumatic brain injury (TBI) in the clinical setting, a phenomenon that translates to pre-clinical animal models as well. In Morris et al. (2021), we reported histological changes following weight-drop-induced TBI in a rodent model including retinal ganglion cell (RGC) loss, decreased electroretinogram (ERG) evoked potential, optic nerve diameter reduction, induced inflammation and gliosis, and loss of myelin accompanied by markedly impaired visual acuity. In this review, we will describe several pre-clinical TBI models that result in injuries to the visual system, indicating that visual function may be impaired following brain injury induced by a number of different injury modalities. This underscores the importance of understanding the role of the visual system and the potential detrimental sequelae to this sensory modality post-TBI. Given that most commonly employed behavioral tests such as the Elevated Plus Maze and Morris Water Maze rely on an intact visual system, interpretation of functional deficits in diffuse models may be confounded by off- target effects on the visual system.
Systems and methods for controlling infusion pump operation based on contextual medical data are provided. Such systems may include a database in memory of a network server. Such a database may store medical information regarding one or more patients. Systems may further include a communication interface that receives infusion pump data from an infusion pump, as well as a processor that executes instructions to identify that the medical information regarding the patient and the received infusion pump data correspond to one or more rules. The processor may also generate control instructions for the infusion pump based on an action associated with the corresponding rules. The communication interface may then send the control instructions to the infusion pump for execution, and the infusion pump may execute the instructions to perform the action associated with the corresponding rules.
This is a pooled analysis from 2 phase III clinical trials investigating a water-free topical cyclosporine 0.1% for the treatment of moderate to severe dry eye. The analyses included 1162 patients: 35% with cataract, 20% with pseudophakia, and 45% without cataract. Demographics or baseline characteristics were comparable across groups except for age and vision. The cyclosporine-treated patients achieved large mean improvements from baseline by day 15: -3.7 in patients without cataract, -3.2 in patients with cataract, and -3.1 in pseudophakic patients. These improvements were statistically significantly higher compared with the respective vehicle groups. In the cataract subgroup, 59% of patients treated with cyclosporine achieved ≥3 grade improvements in corneal staining score, as early as day 15. The magnitude of the effect and early onset of action make this new cyclosporine solution a promising candidate for preoperative management of ocular surface in patients undergoing cataract surgery.
The invention discloses a silkworm excrement brown pigment, and a preparation method and an application thereof. The silkworm excrement brown pigment is a flavonoid water-soluble pigment with a maximal ultraviolet absorption wavelength at 218nm. The preparation method is simple, the cost is low, extraction efficiency is high, and silkworm excrement brown pigment dye uptake is high. After dyeing, cotton, wool, silk, and linen natural fabrics are provided with a golden-brown color. The pigment has high color fastness, excellent anti-ultraviolet ability, certain antimicrobial properties, and comfortable texture. The brown pigment is healthy and environment-friendly. The silkworm excrement brown pigment is an ecological product with a good market prospect.